4-aminobenzoic acid has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies
para-Aminobenzoates: Benzoic acids, salts, or esters that contain an amino group attached to carbon number 4 of the benzene ring structure.
4-aminobenzoate : An aromatic amino-acid anion that is the conjugate base of 4-aminobenzoic acid.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, pharmacokinetic studies in murine models (CD-1 mice) revealed that both SH-4-054 and SH-5-007 are susceptible to glutathione conjugation at the para position of the pentafluorophenyl group via nucleophilic aromatic substitution (SN Ar)." | 1.43 | Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities. ( Ali, AM; Ball, DP; de Araujo, ED; Deininger, MW; Eiring, AM; Gómez-Biagi, RF; Gunning, PT; Heaton, WL; Lai, PS; O'Hare, T; Park, JS; Patel, AB; Rosa, DA; Shouksmith, AE; Vellore, NA, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ali, AM | 1 |
| Gómez-Biagi, RF | 1 |
| Rosa, DA | 1 |
| Lai, PS | 1 |
| Heaton, WL | 1 |
| Park, JS | 1 |
| Eiring, AM | 1 |
| Vellore, NA | 1 |
| de Araujo, ED | 1 |
| Ball, DP | 1 |
| Shouksmith, AE | 1 |
| Patel, AB | 1 |
| Deininger, MW | 1 |
| O'Hare, T | 1 |
| Gunning, PT | 1 |
1 other study available for 4-aminobenzoic acid and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities.
Topics: Animals; Antineoplastic Agents; Biological Availability; Cell Line, Tumor; Cell Proliferation; Dose- | 2016 |